Dynamic Micelles of Mannoside Glycolipids are more Efficient than Polymers for Inhibiting HIV-1 trans-Infection by Schaeffer, Evelyne (Evelyne Schaeffer (e.schaeffer@ibmc-cnrs.unistra.fr)) (author) et al.
Dynamic Micelles of Mannoside Glycolipids are more Eﬃcient than
Polymers for Inhibiting HIV‑1 trans-Infection
Evelyne Schaeﬀer,*,† Laure Dehuyser,‡ David Sigwalt,‡ Vincent Flacher,† Serena Bernacchi,§
Olivier Chaloin,† Jean-Serge Remy,‡ Christopher G. Mueller,† Rachid Baati,‡ and Alain Wagner‡
†Laboratory of Immunopathology and Therapeutic Chemistry, CNRS UPR 3572/Laboratory of Excellence MEDALIS, Institut de
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§Architecture et Reáctivite ́ de l’ARN, CNRS UPR 9002, Institut de Biologie Molećulaire et Cellulaire, Strasbourg, France
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ABSTRACT: Mannoside glycolipid conjugates are able to inhibit
human immunodeﬁciency virus type 1 (HIV-1) trans-infection
mediated by human dendritic cells (DCs). The conjugates are
formed by three building blocks: a linear or branched mannose head,
a hydrophilic linker, and a 24-carbon lipid chain. We have shown
that, even as single molecules, these compounds eﬃciently target
mannose-binding lectins, such as DC-speciﬁc ICAM-3-grabbing
nonintegrin (DC-SIGN) important for HIV-1 transmission. With
the goal to optimize their inhibitory activity by supramolecular
structure formation, we have compared saturated and unsaturated
conjugates, as single molecules, self-assemblies of dynamic micelles,
and photopolymerized cross-linked polymers. Surface plasmon
resonance showed that, unexpectedly, polymers of trivalent
conjugates did not display a higher binding aﬃnity for DC-SIGN than single molecules. Interactions on a chip or in solution
were independent of calcium; however, binding to DCs was inhibited by a calcium chelator. Moreover, HIV-1 trans-infection was
mostly inhibited by dynamic micelles and not by rigid polymers. The inhibition data revealed a clear correlation between the
structure and molecular assembly of a conjugate and its biological antiviral activity. We present an interaction model between
DC-SIGN and conjugateseither single molecules, micelles, or polymersthat highlights that the most eﬀective interactions by
dynamic micelles involve both mannose heads and lipid chains. Our data reveal that trivalent glycolipid conjugates display the
highest microbicide potential for HIV prophylaxis, as dynamic micelles conjugates and not as rigid polymers.
■ INTRODUCTION
Research in the area of nanopharmaceuticals has witnessed an
expansive growth. The elaboration of complex molecular
assemblies of size scales between 1 and 100 nm promises
new advances for therapy and prophylaxis of microbial
infections. For instance, various gold, silver, dendrimer, and
fullerene-based nanotechnologies are being developed as
nanomicrobicides against human immunodeﬁciency virus
type-1 (HIV-1) infections.1 These studies respond to the
urgent need to develop safe and eﬀective mucosal microbicides,
to either inactivate the virus or block its attachment, cell entry,
replication, and transmission.2,3 During the early phase of
sexual transmission, dendritic cells (DCs) play an essential role.
They are among the ﬁrst cells to be infected4−7 and contribute
to viral dissemination by their ability to capture and transport
virions into lymph nodes, eventually mediating infection of new
target cells.8−10 This so-called trans-infection can occur by
distinct pathways. The main mechanism implies the DC-
speciﬁc intercellular adhesion molecule 3 [ICAM-3]-grabbing
nonintegrin (DC-SIGN), a C-type lectin highly expressed at
the surface of DCs.11−13 HIV-1 is captured via DC-SIGN and is
then transferred to target CD4+ cells through cell−cell
interactions.10,14
The DC-SIGN receptor is a membrane protein with an
extracellular C-terminus carbohydrate recognition domain
(CRD), a neck region, and a short amino-terminal cytoplasmic
tail. The CRD tetramer speciﬁcally recognizes glycosylated
proteins and ligands bearing mannose and related sugars. It
interacts with high-mannose structures of glycoproteins in a
calcium-dependent manner and also recognizes fucose-based
ligands such as Lewis X.15,16 The CRD domain binds envelope
glycoproteins expressed on viruses (HIV-1, Ebola, Hepatitis C,
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and Dengue) and many other pathogens.17,18 In the case of
HIV-1, the highly glycosylated glycoprotein gp120 exposed on
the surface of the virion interacts with the carbohydrate
-binding domain of DC-SIGN at the surface of DCs.19−21
The design of DC-SIGN antagonists and carbohydrate
analogues to target distinct receptors has been the focus of
extensive research.22 Eﬀorts were ﬁrst undermined by the
intrinsic low aﬃnity (millimolar binding constants) of
monovalent carbohydrates. The multivalent eﬀect greatly
helped improve binding aﬃnities by orders of magnitude,16
so that multivalent carbohydrate-containing molecules could
eﬃciently target DC-SIGN. Mannose polyvalent dendrimers
and monodisperse compounds interfere in vitro with the
interaction between DC-SIGN and gp120 proteins.23−26
Multivalent mannoside polymers inhibit HIV trans-infection
mediated by DC-SIGN-expressing cell lines. Gold mannoglyco-
nanoparticles block HIV trans-infection mediated by Raji-DC-
SIGN cells27 and are endocytosed in monocyte-derived
immature DCs by DC-SIGN-dependent and -independent
pathways.28 Mannosyl glycodendritic structures based on
dendritic polymers functionalized with mannose also reduce
HIV trans-infection mediated by THP-1-DC-SIGN cells.29 One
of these multimeric glycomimetic DC-SIGN ligands inhibits
HIV-1 trans-infection of CD4+ T lymphocytes and prevents
HIV-1 infection of human cervical tissues.30
We have recently reported the synthesis of mannoside
glycolipid conjugates. These compounds exhibit unusual
properties based on the cooperation between the mannose
head and the lipid chain. Thanks to this original concept, they
target DC-SIGN with micromolar aﬃnities and inhibit HIV-1
(R5 and X4 strains) trans-infection as single molecules and as
self-assembled micelles, with IC50s in the low micromolar
range.25
In this report, we aimed at enhancing the antiviral activity of
our conjugates, by creating multimers of mannoside glycolipids
(micelles and polymers) expected to bind to DC-SIGN with
higher aﬃnities. By building on our previous observation25 that
micelles containing an unsaturated versus a saturated lipid chain
had a 10-fold lower critical micelle concentration (CMC), we
ﬁrst synthesized an unsaturated trivalent glycolipid and
compared it with its saturated homologue. Second, because
we found that photopolymerization of diynes motifs leads to
the reticulation of amphiphilic micelles and decreases their
CMC about 10-fold without aﬀecting their shape and size,31,32
we hypothesized that the inhibitory activity of our compounds
could be optimized by a supramolecular structure of cross-
linked polymers. We evaluated saturated and unsaturated
conjugates, as single molecules, dynamic micelles, and photo-
polymerized cross-linked polymers, with respect to their aﬃnity
for DC-SIGN and their ability to inhibit HIV-1 trans-infection.
Our data demonstrate that dynamic micelles display better
antiviral abilities than rigid polymers. They highlight a clear
correlation between the molecular structure of conjugates and
their antiviral activity.
■ EXPERIMENTAL PROCEDURES
Compound synthesis and characterization are described in
Supporting Information.
Critical Micelle Concentrations (CMC). CMC were
determined as described,25 using conjugate samples dissolved
in water (1 mL), with concentrations ranging from 1.0 to 0.001
mg/mL.
Dynamic Light Scattering (DLS). The hydrodynamic
diameters of micelles were measured in water by DLS
measurements using a Zetasizer Nano ZS system (Malvern
Instruments) as described.31
Polymerization of Micelles. The unsaturated conjugates
were dissolved in water above the micellar concentration (1
mM). Polymerization was performed by irradiation in a UV
chamber (254 nm, 48 W) for 10 h. The resulting solutions were
of yellow color, due to the formation of polymers containing
ene-ynes bonds. This process was reproduced on several
batches that always presented the same functional character-
istics (DLS, biological activity). Concentrations were calculated
as concentrations of monomers before polymerization.
Transmission Electronic Microscopy (TEM). Com-
pounds (5 μL; 0.5 mg/mL) were spread on a copper/rhodium
grid covered with a carbon ﬁlm. Micelles were negatively
stained with uranyl acetate (2%; 50 μL). TEM images were
obtained using a Philips CM 120 microscope.
Surface Plasmon Resonance (SPR). SPR experiments
were performed using a Biacore 3000. Immobilization of
recombinant human DC-SIGN (Lys62-Ala404; R&D Systems)
or recombinant human macrophage mannose receptor MR
(Leu19-Lys1383; R&D Systems) on a CM5 sensor chip (GE-
Healthcare, Uppsala, Sweden) was performed by injecting 70
μL of DC-SIGN, MR, or BSA (50 μg/mL in formate buﬀer, pH
4.3) onto the surface activated with N-ethyl-N′-dimethylami-
nopropyl carbodiimide (EDC)/N-hydroxysuccinimide (NHS),
which gave a signal of approximately 8000 RU. This was
followed by 20 μL of ethanolamine hydrochloride, pH 8.5, to
saturate the free activated sites of the matrix. Biosensor assays
were performed with HEPES-buﬀered-saline (10 mM HEPES,
150 mM sodium chloride, pH 7.4) containing 0.005%
surfactant P20 and 5 mM CaCl2 (or no CaCl2 as indicated)
as running buﬀer. All binding experiments were carried out at
25 °C with a constant ﬂow rate of 20 μL/min. The compounds
dissolved in the running buﬀer (0.39 to 50 μM) were injected
for 3 min, followed by a dissociation phase of 3 min. The sensor
chip surface was regenerated after each experiment by injecting
10 μL of EDTA 0.5 M pH 8.0. A simple channel activated by
EDC/NHS and deactivated with ethanolamine was used as
control. The kinetic parameters were calculated using the
BIAeval 4.1 software. Analysis was performed using the simple
Langmuir binding model with separate ka/kd (kon/koff). The
speciﬁc binding proﬁles were obtained after subtracting the
response signal from the control channel and from blank-buﬀer
injection. The ﬁtting to each model was judged by the χ2 value
and randomness of residue distribution compared to the
theoretical model (Langmuir binding 1:1).
Steady State Fluorescence Spectroscopy. Fluorescence
measurements were recorded in quartz cells at 20 ± 0.2 °C on a
Fluoromax-4 ﬂuorometer (HORIBA Jobin-Yvon Inc., NJ,
USA). The excitation wavelength was set at 295 nm for
selective excitation of tryptophan residues of DC-SIGN. The
emission wavelength was scanned from 310 to 450 nm; the
integration time was 0.1 s, and the excitation and emission
bandwidths were 5 nm. Fluorescence titrations were performed
by adding increasing amounts of conjugate (0.01 to 10 μM) to
DC-SIGN (0.1 μM ﬁnal) in PBS supplemented or not with
CaCl2 (5 mM), as indicated. Fluorescence intensities were
corrected for buﬀer ﬂuorescence and dilution eﬀect. To
determine the binding parameters of the conjugates to DC-
SIGN, we measured the decrease of the ﬂuorescence intensity,
I, at a ﬁxed concentration of protein in the presence of
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increasing conjugate concentrations. The ﬂuorescence intensity
was then converted into the intrinsic ﬂuorescence quenching
Qobs: Qobs = ((I − I0)/(I0)), with I0 corresponding to the
protein ﬂuorescence intensity in the absence of conjugate.
Scatchard equation was used to ﬁt the protein/conjugate
titration data:
= +v
K L
K L1
obs
obs
where Kobs is the observed aﬃnity and L corresponds to the
free protein concentration. In order to check for the presence
of two classes of binding sites for a conjugate, we plotted the
fraction of bound protein versus the unbound protein fraction.
When the plot yielded consistently a linear pattern, we
estimated the presence of only one binding site.
Cell Culture. MAGI-CCR5 cells are HeLa-CD4-LTR-LacZ
cells expressing both CXCR4 and CCR5 coreceptors (received
from NIH AIDS Research and Reference Program, from Dr.
Julie Overbaugh).33 HEK293T cells were used for HIV-1
production. MCF-7 cells were used for viability tests. All cell
lines were cultured at 37 °C and 5% CO2 in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) supplemented with
gentamycin and 10% (v/v) heat-inactivated fetal bovine
serum (FBS).
Human Monocyte-Derived Dendritic Cells (DCs). DCs
were generated from elutriated monocytes obtained from the
French Blood Bank (Etablissement Franca̧is du Sang,
Strasbourg, France) as described.25
Cellular Binding Assays with Fluorescent Conjugates.
A succidinyl ester of Alexa Fluor 633 (AF633; Invitrogen) was
coupled with conjugates 2, 2UP, or with mannan (Sigma-
Aldrich) according to the manufacturer’s instructions. Brieﬂy,
compounds were incubated overnight with AF633 succidinyl
ester (0.05 mol equiv) in H2O (200 μL) with catalytic
quantities of DMAP (10% w/w). Coupled conjugates were
then puriﬁed on PD-10 desalting columns (GE Healthcare)
with quantitative yields.
Elutriated monocytes or immature DCs (105 cells/well in
100 μL of cell culture medium) were seeded in 96-well plates.
Compounds 2/AF633 and 2UP/AF633 (0, 5, or 50 μM) or
Mannan/AF633 (500 μM) were added, and the cells were
incubated for 1 h at 4 °C or at 37 °C, in the presence or
absence of EDTA (50 mM). Cells were harvested and the
geometric mean ﬂuorescence intensity of live cells was
quantiﬁed by ﬂow cytometry in the FL-4 channel.
Flow Cytometry Analyses. Experimental data was
acquired on a FACScalibur (Becton-Dickinson) and analyzed
with CellQuest (BD) or FlowJo (Treestar).
HIV-1 Production. Using molecular clones of HIV-1 NL4-3
R5-tropic version34 was performed as described.25
Figure 1. Structure of conjugates.
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HIV-1 Trans-Infection. Mannoside glycolipids (1.0 or 0.5
mM stock solution in water) were serially diluted in water.
Human DCs (1 × 105 in 200 μL) were pretreated with diﬀerent
concentrations of compounds, mannan (Sigma), or culture
medium alone in RPMI 1640 medium containing 10% FCS for
45 min at 37 °C, prior to infection with HIV-1 (100 ng of
p24Gag) for 3 h. Excess free virus and molecules were removed
by three washes. DCs were then cocultured with MAGI-CCR5
cells (1 × 105) at 37 °C plated in a 48-well plate. After two
days, viral infection of MAGI-CCR5 cells was measured
following beta-galactosidase assays and enumerating blue cells
by light microscopy. The trans-infection assays were repeated a
minimum of three times, and the IC50 values determined using
Kaleidagraph.
■ RESULTS AND DISCUSSION
Synthesis of the Trivalent Unsaturated Glycolipid
Conjugate 2U. We have previously reported that mannoside
glycolipid conjugates ManC24 1, ManC24U 1U, and TriManC24 2
(Figure 1) interact with the extracellular domain of DC-SIGN
and inhibit trans-infection of HIV-1.25 We noticed that the
unsaturated conjugate 1U formed micelles at a 10-fold lower
critical micelle concentration (CMC), compared to the
saturated conjugate 1. Formation of micelles at a low
concentration should optimize the number of mannose heads
interacting with DC-SIGN. In order to decrease the CMC of
the saturated TriManC24 2, we synthesized the corresponding
unsaturated conjugate TriManC24U 2U (Figure 1). For this,
Tris-(carboxyethoxyethyl) aminomethane 5 was reacted with
10,12-pentacosanodiynoic acid to aﬀord the amide 6 that was
hydrolyzed into the triacid 7. Compound 7 was reacted with
amine 8 to aﬀord conjugate 9U. Removal of the acetates led to
the ﬁnal product 2U (Figure 2).
Finally, to further increase the number of mannose heads
susceptible to interact with DC-SIGN, micelles of the
unsaturated mono- and trimannosides 1U and 2U were
photopolymerized, leading to the respective polymers 1UP
and 2UP.
Synthesis of Control Trivalent Glycolipid Conjugates
3 and 4. We have synthesized compound 3, TriManC1 that
lacks the C24-lipid chain, to better evaluate the involvement of
the lipid chain in the binding properties and biological activity.
In addition, to demonstrate the importance of the mannose
moiety, we have synthesized the control compound 4,
TriGalC24, in which the three mannose residues of TriManC24
are replaced by three galactose residues. The synthesis
pathways are described in Supporting Information (Figures
S1, S2).
Physical Properties. All conjugates were soluble in water,
thanks to the presence of the OEG hydrophilic linker. Below
the CMC, mannoside glycolipids exist as single molecules.
Above the CMC, the lipid chains segregate into micelles with
lipids forming a hydrophobic core and the mannose heads
forming a hydrophilic shell. We determined the CMC for each
compound (Figure 3A). Saturated ManC24 1 and TriManC24 2
auto-organized into micelles at a CMC of, respectively, 97 and
109 μM, as described.25 As expected, unsaturated 1U and 2U
displayed roughly a 10-fold lower CMC of respectively 13 and
6 μM.
Micelles are typically described as spherical, nanosized (10−
100 nm) supramolecular assemblies of amphiphilic molecules,
yet smaller than other assemblies, such as liposomes (50−150
nm) or polymeric nanoparticles (10−1000 nm).35 The
hydrodynamic radius and the size distribution of micelles and
polymers of our conjugates were determined by dynamic light
scattering (DLS) in water (Figure 3A). As an example, the
proﬁle for compound 1U is shown in Figure 3B. The
hydrodynamic diameter of saturated ManC24 1 and TriManC24
2 was, respectively, 17 and 39 nm. Unsaturated compounds 1U
and 2U had both a lower value of 11 nm. Polymers 1UP and
2UP had both a hydrodynamic diameter of 16 nm. The
compound 1U could be visualized as 10−20 nm large micelles
by transmission electronic microscopy (TEM) (Figure 3C). In
addition, we found that the size of the compounds were smaller
in PBS than in water: the hydrodynamic diameter of 2 and 2U
(10 μM) were, respectively, 3.2 and 4.3 nm. In PBS containing
calcium chloride, as found in cell culture conditions,
compounds became structured in large assemblies, since the
hydrodynamic diameter of 2 and 2U were increased to,
respectively, 356/742 and 860 nm (Figure S14).
Viability assays performed on a human cell line showed that
saturated conjugates 1 and 2 exhibited no cytotoxicity up to
Figure 2. Synthesis of unsaturated TriManC24U conjugate 2U. Conditions: (i) 10,12-Pentacosadiynoic acid, HOBt, DCC, ACN/THF, reﬂux,
overnight, 57%; (ii) NaOH 4N, THF/EtOH, RT, overnight, 94%; (iii) HOBt, HBTU, DIPEA, THF, reﬂux, overnight, 65%; (iv) NaOCH3, MeOH,
RT, 30 min, 98%.
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500 μM, the highest concentration tested. The unsaturated
conjugate 1U and 2U had no adverse eﬀect on cell viability up
to, respectively, 125 and 250 μM (Figure S15).
Aﬃnities for DC-SIGN and MR. The ability of the
conjugates to interact with DC-SIGN and the mannose
receptor (MR) was measured by surface plasmon resonance
(SPR). A CM5 sensor chip was functionalized with the CRD of
DC-SIGN or MR, and increasing concentrations of the
diﬀerent compounds were injected over the chip surface. The
resulting sensorgrams were evaluated to deduce the association
(kon) and dissociation (koff) rate constants as well as the
resulting dissociation equilibrium constant (KD = koff/kon)
(Figure 4). To assess the speciﬁc binding, compounds were
injected over the chip coated with BSA (Supporting
Information, part D). Kds higher than 13 μM corresponded
to nonspeciﬁc interactions. Our positive control, mannan,
eﬃciently bound to the lectins, while compounds 3 and 4,
without the lipid chain or with a galactose replacing the
mannose unit were unable to bind.
We found that all conjugates displayed better aﬃnities for
DC-SIGN than for MR (Figure 4C, E). The largest diﬀerence
was observed with ManC24 1, which bound with a high aﬃnity
to DC-SIGN (KD of 0.32 μM) but with a low aﬃnity to MR
(KD of 100 μM).
Concerning DC-SIGN, all mono- and trivalent conjugates
exhibited a good aﬃnity in the low micromolar range (Figure
4C). One mannose unit in ManC24 1 and ManC24U 1U was
suﬃcient for interaction, with a KD in the low micromolar
range. The unsaturated trivalent conjugate 2U presented a
better aﬃnity for DC-SIGN (KD = 0.3 μM) than its saturated
homologue 2 (KD = 3.2 μM), suggesting that the unsaturated
chain helped improve the interaction with DC-SIGN.
We next compared the behavior of single unsaturated
molecules with their corresponding polymer. The low
concentrations used in SPR assays for calculation of the
constants correspond to single molecules, and not to micelles.
Results showed that polymerized 1UP and single mono-
conjugate 1U displayed similar association constants (kon), but
1UP had a slower dissociation constant (koff) resulting in a
lower KD. The KD of the polymer 2UP was close to that of the
nonpolymerized 2U. As for MR, polymers presented lower
binding aﬃnity to this lectin (higher KDs) relative to the
nonpolymerized conjugates (Figure 4E). These unexpected
ﬁndings revealed that, with exception of the interaction of 1UP
with DC-SIGN, the presence of multiple mannose heads within
polymerized conjugates decreased rather than increased their
binding aﬃnity for DC-SIGN and MR.
Eﬀect of Calcium on Interactions with DC-SIGN. It has
been established that the interaction of the CRD of DC-SIGN
with high-mannose structures of glycoproteins is multivalent
and calcium-dependent.15,16 To better understand the inter-
actions of our conjugates with C-type lectins and the
importance of the calcium binding site, we performed SPR
analyses in the absence of calcium (Figure 4D, F). Surprisingly,
results with DC-SIGN showed that the absence of calcium did
not prevent binding, as KDs were still in the low micromolar
range (Figure 4D). With TriManC24 2, the aﬃnity for DC-
SIGN even improved in the absence of calcium. With MR, KDs
remained in the micromolar range with 2U and 2UP (Figure
4E). These results showed that, in vitro, our series of mannoside
glycolipids could bind to the extracellular domain of DC-SIGN
in a Ca2+-independent manner. Distinct studies have shown
that when oligosaccharides are decorated with a Manα1−
2Manα structure, the binding by one mannose residue occurs at
the principal Ca2+-binding site, while additional sugar residues
enhance the aﬃnity by providing additional contacts and a
statistical entropic enhancement of binding.21 Similarly, the
lipid chain of our conjugates may cooperate with the mannose
head and enhance the aﬃnity through additional interactions
with various aminoacids of DC-SIGN.
To better evaluate the eﬀect of calcium on the interactions of
mannoside glycolipids with DC-SIGN, we measured the
intrinsic ﬂuorescence emission of DC-SIGN, in solution in
PBS. In the presence of calcium, the ﬂuorescence intensity
decreased with increasing concentrations of compound 2
(Figure 5A). The intensity of ﬂuorescence was converted into
the ﬂuorescence quenching parameter (Figure 5B), which led
to the determination of the Kd (Figure 5C), as described in
Experimental Procedures. Interestingly, the model of two sites-
ﬁt led to two distinct Kds of 72 and 800 nM, likely reﬂecting
distinct interactions of the mannose moiety and the lipid chain.
In the absence of calcium, the intensity of ﬂuorescence ﬁrst
decreased and then increased at about 1 μM. Thus, a Kd of 64
nM was calculated at low concentrations (Figure S11).
Similarly, compound 2U interacted with DC-SIGN, with and
without calcium, and displayed a respective Kd of 180 and >305
nM (Figure 5D and S12−S13). These results conﬁrmed the
ability of our compounds to interact with the DC-SIGN protein
in solution, with and without calcium.
Next, we investigated the requirement for calcium in a
cellular assay. Conjugates 2 and 2UP were ﬂuorescently labeled
with Alexa-Fluor 633 (AF633). Monocytes that lack DC-SIGN
expression, and DCs that express high levels of DC-SIGN25,36
were incubated in the presence of the labeled conjugates for 1 h
and the mean ﬂuorescent intensity (MFI) of the cells was
determined by ﬂow cytometry (Figure 6A). The intensity of
ﬂuorescence reﬂects both cell-surface binding and internal-
ization. As expected, results showed that at 4 °C compounds
bound to the cell surface at a low level, since internalization
Figure 3. Characterization of mannoside glycolipid micelles: (A)
CMC and diameter of micelles (nm). (B) Size distribution for the
micelles of 1U. (C) TEM pictures for micelles of 1U (scale bar: 50
nm).
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does not occur at this temperature. At 37 °C, the intensity of
ﬂuorescence was increased, as a consequence of the internal-
ization of the compounds in addition to cell surface binding.
DCs showed strong and dose-dependent interactions with both
conjugates, reﬂecting the eﬃcient binding to DC-SIGN, and to
a lower extent to MR. Monocytes interacted with conjugates,
albeit at much lower levels; this binding may depend on other
receptors, such as heparan sulfates.37
To examine the importance of calcium for DCs−conjugates
interactions, DCs were incubated with the labeled compounds
in the presence or absence of EDTA (Figure 6B). Mannan that
binds to DC-SIGN in a calcium-dependent manner (see legend
of Figure 4) was also labeled with AF633 and used as a control.
Interactions of DCs with mannan were decreased from 100% to
45% in the presence of EDTA. A similar inhibition (∼50%) was
seen for 2 and 2UP. These results suggest that interactions of
the conjugates with DC-SIGN expressed at the DC cell surface
are dependent on the calcium binding site of the CRD.
Finally, we examined whether mannan can compete with 2
and 2UP. DCs that were preincubated with 1 mM mannan for
30 min at 37 °C showed a 55% decrease in their ability to bind
2 and 2UP (Figure 6C). This potent, but incomplete, inhibition
suggests that interactions of 2 and 2UP with their target
receptor(s) on DCs mostly rely on their mannose moiety.
Comparison of Micelles and Polymers for Inhibition
of HIV-1 trans-Infection. We investigated the ability of the
conjugates to inhibit HIV-1 trans-infection, mediated by
infected human DCs. These cells mimic in vivo conditions of
viral infection by mucosal DCs. The DCs were pretreated with
the diﬀerent compounds for 45 min at 37 °C, before exposure
to HIV-1 (R5 strain). After 3 h of incubation, cells were
extensively washed to remove unbound virions and compounds
and were then cocultured with reporter MAGI-CCR5 cells.
These cells express the CD4 receptor and the CCR5 coreceptor
required for cell entry and fusion of HIV-1 R5. They also
express an integrated copy of the HIV long terminal repeat
fused to the beta-galactosidase reporter gene and thus allow
precise quantiﬁcation of HIV-1 replication by detection of beta-
galactosidase activity.
Figure 4. Direct binding by surface plasmon resonance (SPR) of mannoside glycolipid conjugates to DC-SIGN or mannose receptor (MR)
immobilized on a CMS sensor chip. (A, B) Sensorgram of the binding of 2U to DC-SIGN and MR immobilized via amino groups. The binding
response (in RU) was recorded as a function of time. (C, D, E, F) Kinetic parameters of interactions determined in the presence (C, E) or absence
(D, F) of CaCI2. As a positive control, binding of mannan was detected at 10 μg/mL (corresponding to 62 μM of mannose units) in the presence of
CaCI2. Mannan was unable to bind up to 280 μM of mannose units in the absence of CaCI2. kon, kinetic association rate; koff, kinetic dissociation
rate; KD, equilibrium dissociation constant; Rmax (RU), maximal response expressed as resonance units; χ
2, chi square value. 1:1 Langmuir binding
model was used for all compounds. ″Low b.″: Low binding. ″No b.″: No binding. ND: not determined.
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We ﬁrst tested the compounds at 10 and 100 μM (Figure 7).
As expected, the control compounds 3 and 4 were unable to
inhibit HIV-1 trans-infection. All trivalent conjugates were more
active than monovalent conjugates, conﬁrming our previous
report.25 Surprisingly, the polymer 1UP was totally inactive.
Even at the highest concentration of 100 μM, this polymer only
marginally aﬀected trans-infection, in contrast with non-
polymerized 1U. The disadvantage of a rigid polymerized
structure was conﬁrmed with polymer 2UP, which displayed a
lower inhibitory activity, relative to the micelles formed by 2U.
These results showed that within a cellular context, rigid
polymeric assemblies of mannoside glycolipids were unable to
eﬃciently protect MAGI-CCR5 cells from HIV-1 trans-
infection.
Comparison of Unsaturated and Saturated Conju-
gates for Inhibition of HIV-1 trans-Infection. Dose−
response experiments were performed to compare the
inhibitory capacity of unsaturated and saturated conjugates.
We determined the concentration at which there was 50%
inhibition of trans-infection (IC50). Monomannoside glycolipids
1 and 1U were active at concentrations higher than 1 μM, and
displayed IC50s of, respectively, 120 and 61 μM (Figure 8A). At
high concentrations, they reduced viral trans-infection down to
a residual level of about 20%.
Trivalent conjugates 2 and 2U exhibited a powerful
inhibitory activity, as reﬂected by low IC50s of, respectively,
0.501 μM and 0.305 μM (Figure 8B). Unsaturated 2U was
more active than saturated 2 at high concentrations, since the
residual level of infection was reduced, respectively, to 2% and
20%. The better inhibitory activity of unsaturated 2U correlated
with its better aﬃnity for DC-SIGN, in agreement with our
SPR data (Figure 4C).
Figure 5. Binding of mannoside glycolipid conjugates to DC-SIGN in solution measured by emission ﬂuorescence spectroscopy. (A) Emission
ﬂuorescence spectra of DC-SIGN in solution (PBS with 5 mM CaCl2) and in the presence of increasing concentrations of conjugate 2. Excitation
wavelength was set at 295 nm. (B) The ﬂuorescence intensity I was then converted into the ﬂuorescence quenching parameter Qobs (as described in
Experimental Procedures). (C) Determination of the equilibrium dissociation constant, Kd, using the one-site and two-sites model ﬁt. (D) Kd of DC-
SIGN with indicated conjugates, in the presence and absence of CaCl2.
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We observed that the dose−response inhibition proﬁle was
diﬀerent for conjugates 2 and 2U (Figure 8B). The saturated 2
displayed a progressive decrease with a constant slope a,
between 0.01 and 250 μM. The unsaturated 2U displayed two
distinct slopes: slope a at low concentrations (0.01 to 1 μM),
and a faster slope b at high concentrations (10 to 250 μM). The
cutoﬀ range between 1 and 10 μM corresponds to the CMC
(6.4 μM). Similarly for compounds 1U and 2U, a fast slope b
was detected at concentrations above the CMC, which shows
that micelles induce a better inhibition rate compared with
single molecules (Figure 8C). This result revealed that single
molecules and micelles induce an antiviral inhibitory activity
with distinct eﬃciencies, reﬂected by the respective slow slope a
and fast slope b. Thus, our ﬁndings point out a clear correlation
between the molecular assembly of a conjugateeither single
molecules or a micelleand its antiviral inhibitory activity.
They demonstrate that multivalent mannose presentation in
micelles is most eﬃcient for the biological inhibition of viral
transmission.
Figure 6. Interactions of mannoside glycolipid conjugates with human DCs and monocytes measured by ﬂow cytometry. (A) DCs and monocytes
were incubated with ﬂuorescently labeled conjugates 2/AF633 or 2UP/AF633, for 1 h at either 4 °C or at 37 °C. One representative experiment out
of three with similar results is shown. (B) Comparison of ﬂuorescently labeled mannan or conjugates 2/AF633 and 2UP/AF633 (5 μM)
interactions with DCs after a 1 h incubation at 4 or 37 °C, in the absence or presence of EDTA at 37 °C. (C) DCs were incubated with mannan (1
mM) for 30 min at 37 °C, before addition of ﬂuorescently labeled conjugates 2/AF633 and 2UP/AF633 (5 μM) for 1 h at 37 °C. Values were
normalized to the mean ﬂuorescence intensity (MFI) measured at 37 °C in the absence of EDTA. One representative experiment out of three with
similar results is shown.
Figure 7. Comparison of micelles and polymers of mannoside glycolipid conjugates for inhibition of HIV-1 trans-infection. Human DCs were
pretreated with the indicated compounds for 30 min at 37 °C and infected with HIV-1 R5. After extensive washes, DCs were cocultured with MAGI-
CCR5 cells for 2 days. Viral trans-infection was quantiﬁed. Values were normalized relative to 100% infection obtained with medium alone. Mannan
was used as a positive control. Values are means ± SE from data obtained from at least three independent experiments.
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■ CONCLUSIONS
Our studies revealed that mannoside glycolipids display the
highest biological antiviral activity when structured as dynamic
micelles in equilibrium with single molecules, rather than as
rigid cross-linked polymers. Moreover, our data have
demonstrated a clear correlation between the structure of the
molecular assemblyas a single molecule, a micelle or a
polymerand its corresponding biological activity.
Our SPR results ﬁrst revealed a novel aspect of the
interactions between mannoside glycolipid conjugates and the
DC-SIGN protein. While interactions with C-type lectins are
dependent on the proper conformation of their calcium-binding
site, as shown with mannan, our conjugates were able to
interact in vitro with the CRD of monomeric DC-SIGN both in
the presence and the absence of calcium, with KDs in the
micromolar range. Similarly, steady-state ﬂuorescence spectros-
copy data conﬁrmed that interactions occur with DC-SIGN in
solution, with and without calcium, with Kds in the low
micromolar range. This result agrees with previous studies
reporting that proteins of the C-type lectin family can bind
some sugars in the absence of calcium: CLEC5A does not have
a full set of calcium-coordinating and carbohydrate binding
sites;38 dectin-1 binds β-glucan oligosaccharides in the absence
of calcium;39 concerning DC-SIGN, our ﬁnding emphasizes the
role of the lipid chain present in our conjugates, which may
interact with a hydrophobic pocket of the protein located
outside of the calcium binding site. The emission ﬂuorescence
spectra data revealed two distinct Kds for TriManC24, which
likely reﬂect the binding of the mannose moiety and the lipid
chain. However, in contrast with our SPR and ﬂuorescence
data, the calcium dependence was observed in a cellular
environment. Our DLS data have revealed that in the presence
of calcium, the conjugates form large structured assemblies.
One may thus envision that larger conjugates display optimal
interactions with DC-SIGN expressed at the surface of DCs.
Mannoside glycolipid conjugates exist in the form of either
single molecules or assemble into self-organized micelles, which
both target DC-SIGN and block HIV-1 trans-infection, as
shown previously.25 The aﬃnity of these conjugates for DC-
SIGN and their inhibition of HIV-1 trans-infection are based on
the cooperation between the lipid chain and the linked
mannose moiety. Thanks to this cooperation, monomannoside
glycolipid conjugates (1 and 1U) target DC-SIGN and inhibit
HIV-1 trans-infection even as single molecules. The inhibitory
activity was improved by multivalent presentation of three
mannoses in the saturated TriManC24 (conjugate 2). However,
its CMC of 109 μM lead to micelles formation at a high
concentration. The design and synthesis of unsaturated
TriManC24U (conjugate 2U) helped reduce the CMC to 6
μM. As expected, formation of micelles at a lower
concentration improved the biological eﬃciency: 2U was
most eﬀective for reducing trans-infection to a minimal residual
level, at high concentrations. These data highlight the
importance of designing molecules able to self-assemble into
micelles at the lowest CMC possible.
Our data further demonstrate that formation of a scaﬀold
oﬀering a multivalent mannose presentation reduced HIV-1
trans-infection mostly when the structure was organized as
dynamic micelles, in equilibrium with single molecules. In
contrast, when conjugates were structured as rigid photo-
polymerized cross-linked polymers, they were much less
eﬀective as inhibitors. A putative model accounting for these
ﬁndings is presented in the TOC graphic. Single conjugates
display high aﬃnity interactions with DC-SIGN, thanks to
multiple interactions of their mannose head and lipid chain.
However, optimal interaction with DC-SIGN is hampered by
the low concentration of single molecules, which results in low
antiviral activity (left scheme). Micelles possess two advantages:
ﬁrst, they concentrate multiple conjugates susceptible to target
DC-SIGN; second, within micelles, lipid chains are free to
move into an optimal interaction with DC-SIGN. Thus, the
high conjugate concentrations and the dynamic properties of
micelles lead to optimal interactions, which result in the highest
antiviral activity (central scheme). However, within photo-
polymerized cross-linked polymers, lipid chains are caged inside
the macromolecular structure, thus unable to interact with a
hydrophobic pocket of the protein located outside of the
calcium binding site of DC-SIGN. Due to their rigid structure,
polymers have the disadvantage to target DC-SIGN exclusively
via their mannose moieties, which leads to low antiviral activity
(right scheme). Together, these data highlight the importance
of designing conjugates susceptible of dynamic possibilities, and
enough freedom for adjusting to optimal interactions with a
cellular receptor. The fact that micelles are more eﬀective than
the corresponding cross-linked polymers suggests that building
a level of dynamic plasticity into the multivalent presentation of
the ligand helps to adapt to the complex membrane
organization of the receptor. However, the inactivity of the
polymer could also result from other structural feature of the
Figure 8. Dose−response inhibition of HIV-1 trans-infection by mannoside glycolipid conjugates. HIV-1 trans-infections between human DCs and
MAGI-CCR5 cells were performed as described in Figure 7, at the indicated concentrations with (A) monovalent-conjugates, (B) trivalent
conjugates, and (C) unsaturated mono- and trivalent-conjugates. The critical micelle concentration (CMC) is indicated. Slopes a and b are indicated.
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material, for instance, excessive reticulation, which prevents
exposure of the sugar at the polymer surface.
Further studies are required to investigate the ability of our
conjugates to prevent mucosal HIV-1 transmission in humans.
It will also be important to assess whether our compounds do
not impair the mucosal integrity or induce inﬂammatory
processes. Once the physiological safety of these conjugates is
shown, they could be considered as novel tools for HIV
prophylaxis.
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